

# Diabetologia

Journal of the  
European Association  
for the Study  
of Diabetes (EASD)

Clinical and Experimental Diabetes and Metabolism

Volume 39 · Number 3 · March 1996

## Originals

**H.-P. Hammes, A. Weiss, D. Führer, H. J. Krämer, C. Papavassiliis, F. Grimminger**  
Acceleration of experimental diabetic retinopathy in the rat by omega-3 fatty acids 251

**L. Rosenberg, A. I. Vinik, G. L. Pittenger, R. Rafaeloff, W. P. Duguid**  
Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor(s) 256

**M. Sagara, J. Satoh, R. Wada, S. Yagihashi, K. Takahashi, M. Fukuzawa, G. Muto, Y. Muto, T. Toyota**  
Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine 263

**M. P. Cohen, R. S. Clements, J. A. Cohen, C. W. Shearman**  
Prevention of decline in renal function in the diabetic *db/db* mouse 270

**F. Thaiss, G. Wolf, N. Assad, G. Zahner, R. A. K. Stahl**  
Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats 275

**J. Markussen, S. Havelund, P. Kurtzhals, A. S. Andersen, J. Halstrøm, E. Hasselager, U. D. Larsen, U. Ribel, L. Schäffer, K. Vad, I. Jonassen**  
Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs 281

**G. Sesti, R. D'Alfonso, M. D. Vargas Puntì, A. N. Tullio, Y. Y. Liu, M. Federici, P. Borboni, M. A. Marini, R. Lauro, A. Fusco**  
Delayed intracellular dissociation of the insulin-receptor complex impairs receptor recycling and insulin processing in cultured Epstein-Barr virus-transformed lymphocytes from insulin-resistant subjects 289

**J. M. Mooy, P. A. Grootenhuys, H. de Vries, P. J. Kostense, C. Popp-Snijders, L. M. Bouter, R. J. Heine**  
Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study 298

**J. R. Zierath, A. Handberg, M. Tally, H. Wallberg-Henriksson**  
C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation 306

**M. Majer, D. M. Mott, H. Mochizuki, J. C. Rowles, O. Pedersen, W. C. Knowler, C. Bogardus, M. Prochazka**  
Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians 314

**R. W. Taylor, R. L. Printz, M. Armstrong, D. K. Granner, K. G. M. M. Alberti, D. M. Turnbull, M. Walker**  
Variant sequences of the Hexokinase II gene in familial NIDDM 322

**S. Tesfaye, R. Malik, N. Harris, J. J. Jakubowski, C. Mody, I. G. Rennie, J. D. Ward**  
Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis) 329

**M. E. Plater, I. Ford, M. T. Dent, F. E. Preston, J. D. Ward**  
Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function 336

**A. Veves, V. M. Donaghue, M. R. Sarnow, J. M. Giurini, D. R. Campbell, F. W. LoGerfo**  
The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients 344

## Rapid communications

**T. Fujisawa, H. Ikegami, E. Yamato, K. Takekawa, Y. Nakagawa, Y. Hamada, T. Oga, H. Ueda, M. Shintani, M. Fukuda, T. Ogihara**  
Association of Trp64Arg mutation of the  $\beta$ 3-adrenergic-receptor with NIDDM and body weight gain 349

**A. Sainsbury, I. Cusin, P. Doyle, F. Rohner-Jeanrenaud, B. Jeanrenaud**  
Intracerebroventricular administration of neuropeptide Y to normal rats increases *obese* gene expression in white adipose tissue 353

## For debate

**G. Paolisso, D. Giugliano**  
Oxidative stress and insulin action: is there a relationship? 357

**L. Cominacini, U. Garbin, V. Lo Cascio**  
The need for a 'free radical initiative' 364

## Letters to the editors

**H.-H. Parving**  
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy 367

**K. S. L. Lam**  
Response from the authors 368

**R. Bender**  
The effect of cholesterol-lowering therapy on the progression of diabetic nephropathy is unproved 368

**K. S. L. Lam, I. J. Lauder**  
Response from the authors 369

**R. Lorini, M. Vanelli**  
Normal values of first-phase insulin response to intravenous glucose in healthy Italian children and adolescents 370

**M. Mizota, Y. Uchigata, S. Moriyama, K. Tokunaga, N. Matsuura, J. Miura, T. Juji, Y. Omori**  
Age-dependent association of HLA-A24 in Japanese IDDM patients 371

**T. Awata, T. Izumida, C. Kikuchi, S. Katayama**  
Response from the authors 373

## EASD News Section 21



0012-186X(199603)39:3;1-7

Indexed in Current Contents and Index Medicus

DBTGAJ 39 (3) 251-374 (1996)  
Printed on acid-free paper

## DUALITY OF INTEREST DISCLOSURE FORM FOR AUTHORS OF ARTICLES IN AMERICAN DIABETES ASSOCIATION PUBLICATIONS

I have read the American Diabetes Association's Duality of Interest Policy Statement (found in the January and July issues of *Diabetes* and *Diabetes Care*), and I am indicating below that I have or have not had in the previous 12 months a relevant duality of interest with a company whose products or services are *directly* related to the subject matter of my manuscript. A relevant duality of interest includes employment, membership on the board of directors or any fiduciary relationship, membership on a scientific advisory panel or other standing scientific/medical committee, ownership of stock, receipt of honoraria or consulting fees, or receipt of financial support or grants for research. Company is defined as a for-profit concern engaged in the development, manufacture, or sale of pharmaceutical or biomedical devices or supplies.

**Each author must sign this form.** (The form may be photocopied if needed.)

	Check each area that applies					
	Yes	No	Yes	No	Yes	No
Employment	_____	_____	_____	_____	_____	_____
Membership on an advisory panel, standing committee, or board of directors	_____	_____	_____	_____	_____	_____
Stock shareholder	_____	_____	_____	_____	_____	_____
Honoraria or consulting fees	_____	_____	_____	_____	_____	_____
Grant/research support	_____	_____	_____	_____	_____	_____
Author (please type or print)	_____		_____		_____	
Signature	_____		_____		_____	
Date	_____		_____		_____	

For each item checked "yes," please list on a separate sheet of paper the third-party organization with whom you have relevant affiliations or interests. Please provide sufficient information to enable the American Diabetes Association to make an informed decision. Include 1) the nature of the activity that is a relevant duality, 2) the type of financial arrangement, if any, between you and the third party, and 3) a description of the business or purpose of the third party. Please see the following sample disclosures.

### **SAMPLE DISCLOSURES FOR AUTHORS**

#### **Employment**

I am employed by Exacta Pharmaceutical Company (6250 Longwood Avenue, Any City, Missouri). My employer manufactures and markets pharmaceuticals related to the treatment of diabetes and its complications.

#### **Board Membership**

I am on the board of directors of the Exacta Pharmaceutical Company, a manufacturer of pharmaceuticals related to the treatment of diabetes.

#### **Stock Shareholder**

I, or my immediate family, hold stock in the following companies that make products related to the treatment or management of diabetes and its complications:

XYZ Corporation  
LMN Corporation

#### **Honoraria or Consulting Fees**

I have received honoraria for speaking engagements from the following:

XYZ Corporation  
LMN Corporation

I am a paid consultant of the XYZ Corporation.

#### **Grants**

The XYZ Corporation is providing funds to my laboratory in order to conduct studies on a new drug to treat diabetic neuropathy.

By answering "yes" in any category, the Association will disclose the relevant duality of interest. The Association will make the disclosure by placing an asterisk by the author's name, and in a footnote describe the nature of the duality of interest, e.g., stock ownership or grant support, and the third party involved.

**This form must be returned with your submission. Make additional copies as needed for all authors. Failure to complete the disclosure may delay or prevent publication of your article.**

## COPYRIGHT TRANSFER AND STATEMENT OF ORIGINALITY

We approve the submission of this paper to the American Diabetes Association for publication and have taken due care to ensure the integrity of this work. We confirm that neither the manuscript nor any part of it has been published or is under consideration for publication elsewhere (abstracts excluded). Any reference to or use of previously published material protected by copyright is explicitly acknowledged in the manuscript.

If this work was produced by an employee of the United States Government as part of his/her official duties, no copyright exists and therefore cannot be transferred. Any co-authors **not** employed by the federal government must sign the copyright transfer agreement.

If this work was produced for an employer as a "work made for hire," an authorized representative of that employer must sign on the appropriate line below.

The undersigned hereby assign copyright for the manuscript entitled

\_\_\_\_\_  
\_\_\_\_\_

to the American Diabetes Association upon its acceptance for publication (attach an additional page for signatures if necessary; **all** authors must sign):

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

The above title constitutes a "work for hire"; as an authorized agent of the employer, I transfer copyright to the American Diabetes Association (no patent rights are transferred):

\_\_\_\_\_  
Agent

\_\_\_\_\_  
Title

This work was produced on behalf of the United States Government and therefore no copyright exists.

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

\_\_\_\_\_  
(Author)

**ABSTRACT PREPARATION GUIDELINES****GENERAL INFORMATION**

1. Abstracts must be received at the Association's National Center by Monday, January 6, 1997.

2. Abstracts are not eligible if the paper has been presented at another national or international meeting or has been accepted for publication before the abstract submission deadline and will be published prior to the 57th Scientific Sessions. Failure to notify the Association of the publication of an abstract will result in a moratorium on the submission of abstracts for all authors appearing on the abstract in question for one year.

3. The printed abstract must be an original, submitted on the original abstract forms found in this packet. Abstracts cannot be submitted via fax.

4. An individual (member or non-member) may appear on four abstracts as an author, but may only appear as first author on two abstracts. A member may appear as author, co-author, or sponsor. A non-member may appear as author or co-author, but not as a sponsor. Authors are not required to be members of the Association.

5. Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts. Make abstracts as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods or what was done, the results observed, and the author(s)' conclusions based on the results. Actual data should be summarized. It is inadequate to state "The results will be discussed" or "The data will be presented." Tables may be used to present data (refer to #18 in the instructions)

6. The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Association's Scientific Sessions Meeting Committee.

7. Accepted abstracts will be printed as submitted. Changes to abstracts will not be accepted after submission. They should be carefully written and edited prior to submission.

8. For additional abstract packets, or if you have questions about completing the abstract form, contact Sandy DeVault, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA; phone: 703/549-1500, ext. 2096; FAX: 703/683-1839; E-mail: sdevault@diabetes.org.

9. Oral presentations at the Scientific Sessions will be limited to ten minutes each to allow time for discussion.

10. Expenses associated with the submission and presentation of the abstract are the responsibility of the presenter.

11. Presenters must pay the registration fee for attendance at the Scientific Sessions. Presenters will be able to register at pre-registration rates. For more information on registration, contact the Meeting Services Department, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA; phone: (703) 549-1500, ext. 2453 or 2330; FAX: (703) 683-1351; E-mail: meetings@diabetes.org.

**COMPLETING THE FORMS**

12. Accepted abstracts will be reduced by 25% and photographed as submitted for publication in the 57th Abstract Book, the May supplement to *Diabetes*. We recommend using a font no smaller than 10 points.

13. The text must be clear, within the border of the form, and limited to the space provided. Use only a typewriter or laser printer, as the quality of dot matrix printers varies considerably. Those with text exceeding the border will not be accepted. Text glued or taped inside the border will be accepted. Please use the following tips when printing your abstract:

■ If typed, use carbon ribbon or slightly used black silk ribbon (new ribbons smudge, old ones reproduce too faintly). Practice typing the abstract in a rectangle 4 3/16" (10.64 cm) X 6 3/16" (15.42 cm) before using the original form.

■ If using a laser printer, please note that the page size of the form is not standard. A left margin of 1.15" (2.92 cm) and a right margin of 3.35" (8.51 cm) should keep the text within the border. Practice printing the abstract with these margins before using the original form.

14. Abstract headings must follow a specified format. The format is as follows (refer to the example below):

a. Headings should begin to the immediate right of the box located in the upper left corner of the abstract area.

b. The first letters of major words in the title should be capitalized. Do not use subtitles (e.g., Methods, Results) in the abstract body.

c. Author(s)' complete first and last name(s) should be listed and capitalized. Authors who appear on more than one abstract should list their names the same way on all.

d. Author(s) who are members of the Association's Professional Section must be indicated by an asterisk (\*) after their name. No other identifying marks are permissible except as noted in "e." below.

e. Author(s) who indicate "yes" on the *Duality of Interest Disclosure Form* (see pg. 6) must include a notation after their name(s). Use the following to indicate the type of duality: 1= any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers(s) of commercial services discussed in the educational presentation; 2 = any significant financial interest or other relationship with any commercial supporters of the activity.

f. Do not list credentials, degrees, academic title(s) (e.g., MD, RN, RD), departments, divisions, or institutional affiliation(s) on the abstract form.

g. Include city and state (postal abbreviations) or country of origin of work; do not include street address and zip code.

**Example of abstract heading:**

A Novel Form of Chelatin Prevents IDDM in BB Rats.  
JOHN DOE<sup>1</sup>, JAMES E. REASONER\*, SUSAN SMITH<sup>2</sup>,  
JANE FRIDAY<sup>2</sup>, Alexandria, VA

15. The first line of the text of the abstract and first line of any subsequent paragraphs should be indented three spaces.

16. The use of standard abbreviations is requested. Examples include kg, g, mg, ml, L (liter), meq, m (meter), mM (millimoles per liter), / (per), and % (percent). Place special or unusual abbreviations in parentheses after the full word the first time it appears, then use the abbreviation throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning sentences.

17. Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; names are always capitalized, for example, aspirin (Bufferin).

18. Simple tables or special symbols may be included if they fit within the border of the form. Material that cannot be typed should be drawn in India ink.

19. Do not include references, credits, or grant support information in the abstract.

20. The Scientific Sessions Meeting Committee will consider presentation preference when planning the program. An abstract marked as "Only" (see Forms, pages 3 and 5) indicates that the authors do not want an abstract considered for any other type of presentation. For example, if an abstract is marked as "Oral Only" and is not selected for an oral presentation, the committee will not place the abstract in a poster session. Marking an abstract as "Oral Only" will not guarantee its selection for the program.

21. Categories for the 57th Scientific Sessions are located on page 4. Indicate the appropriate category under which you wish to have the abstract reviewed on both Form A and Form B. The Scientific Sessions Meeting Committee reserves the right to move an abstract that has been inappropriately categorized without notifying the author(s).

22. The signature of an active member of the Professional Section of the American Diabetes Association is required to validate the abstract. Members who sponsor non-members should verify that the latter are conforming to the rules. A member is not limited to the number of abstracts he/she can sponsor.

23. All authors must read and sign the *Duality of Interest* form (page 6) and this form must be included with each abstract submitted. Please refer to #14e for instructions on noting dualities on the abstract form. When preparing abstracts, please allow enough time to have all authors sign the original form.

24. Provide the information requested for the corresponding author, who will receive notification of abstract status (#28).

25. If the research presented in this abstract has been supported, in whole or in part, by a grant from the American Diabetes Association, please indicate so by checking on the appropriate line. Accepted abstracts with Association funding will be highlighted in the Final Program of the 57th Scientific Sessions. The response provided to this question will not affect the acceptance of abstracts for the 57th Scientific Sessions.

26. Before mailing an abstract submission, use the checklist on page 7 to confirm that all instructions have been followed and all items have been included in the submission packet.

## ACKNOWLEDGEMENT OF RECEIPT AND ABSTRACT STATUS

27. For acknowledgment that an abstract was received by the Association, you must provide a self-addressed, US stamped postal card addressed to the corresponding author. The reverse side of the card should indicate the title of the abstract. Confirmation of receipt cannot be made by phone.

28. A letter of notification and appropriate accompanying materials will be sent by mail to the corresponding author. In addition, all international correspondence will be sent by Internet E-mail or fax if the appropriate numbers are included on form A.

## MAILING SUBMISSION

29. A non-refundable processing fee of US \$35.00 and a completed payment form (see page 7) must accompany each abstract submitted to the American Diabetes Association. Payment must be in the form of a check or credit card. Checks must be in U.S. funds and drawn on a U.S. bank, and made payable to the *American Diabetes Association*. Major credit cards (American Express, VISA, MasterCard) are also accepted. Purchase orders and money orders will not be accepted.

30. The review of abstracts is blinded, therefore two forms must be submitted: one (1) for publication (Form A) with the title and author(s)' name(s) within the border of the form, and one (1) for review (Form B) without author information. Please refer to Abstract Forms A and B on pages 3 and 5 for further instructions.

31. Five (5) copies of the front only of each form must also be provided for processing.

32. Do not fold the originals or copies. They should be mailed FIRST CLASS or AIR MAIL, when applicable, and addressed as follows: Scientific Sessions Meeting Committee, American Diabetes Association, P.O. Box 26427, Alexandria, VA 22313-6427, USA. Abstracts sent by express mail should be addressed as follows: Scientific Sessions Meeting Committee, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA. When shipping express mail, do not ship for a Saturday arrival. **Abstracts submitted via fax will not be accepted for review.**

## "LATE-BREAKING RESEARCH" ABSTRACTS

33. Late-breaking research abstracts will be peer-reviewed, and only those deemed **highly meritorious** will be accepted for presentation. Selected abstracts will be presented during the President's Poster Session. "Late-breaking research" abstracts will not be published in the Abstract Book, nor will they appear in the Final Program because of printing deadlines. Authors should use the forms and follow instructions found in this packet. The appropriate box on Form A must be check marked, and all submissions must be received by May 16, 1997. The processing fee for abstracts in this classification is \$50. "Late-breaking research" abstracts must be sent to the attention of Sandy DeVault, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447 USA. Notification of abstract status will be provided no later than May 30, 1997.

**TYPE ABSTRACT WITHIN BOX**

List family name, first name, middle initial, credentials/degrees, address (including city/state/country/zip), and telephone/fax numbers of author who should receive correspondence (please type or print):

Family Name \_\_\_\_\_

First Name \_\_\_\_\_ MI \_\_\_\_\_

Credentials/Degrees \_\_\_\_\_ Department \_\_\_\_\_

Institution \_\_\_\_\_

Street Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Country \_\_\_\_\_ Zip Code/Postal Code \_\_\_\_\_

Phones (include area code/country/city code): Work: \_\_\_\_\_ Fax: \_\_\_\_\_

Has this research been supported, in whole or in part, by a grant from the American Diabetes Association? \_\_\_ Y \_\_\_ N

Internet E-mail address: \_\_\_\_\_ (International submitters must include for timely notification)

**FOR OFFICE USE ONLY**

Date Rec'd \_\_\_\_\_ PMT? \_\_\_\_\_

Abstract No. \_\_\_\_\_

Duality? \_\_\_ Y \_\_\_ N Signed? \_\_\_ Y \_\_\_ N

Record No. \_\_\_\_\_

Mean Score \_\_\_\_\_



**FORM A**  
(For publication)

**CHECK ONE (See #21):**

- Poster Session Preferred       Oral Session Preferred
- Poster Session Only       Oral Only
- No Preference

The author's wishes will be followed if possible.

I am submitting this abstract after January 6, 1997 as "late-breaking research" (See #33).

**Abstract Category Number:** \_\_\_\_\_  
(Categories listed on pg 4)

**IMPORTANT**

**This form must be signed by an active member of the Professional Section of the American Diabetes Association.**

The instructions on pages 1 and 2 must be followed exactly for abstracts to be considered for review.

The sponsoring member agrees that the material submitted herein conforms with the instructions on pages 1 and 2.

\_\_\_\_\_  
**MEMBER SIGNATURE**

\_\_\_\_\_  
**PRINTED NAME**

***PLEASE LEAVE THIS AREA BLANK***

---

***1997 ABSTRACT CATEGORIES***

Select **one** two-digit category number and enter it on the appropriate line on both Abstract Form A and Abstract Form B:

- |   |                                       |  |
|---|---------------------------------------|--|
| 01 Clinical Diabetes                        | 10 Forms of Therapy/New<br>Technology | 19 Metabolism, in vitro                |
| 02 Complications, Hypoglycemia<br>and Other | 11 Gene Regulation                    | 20 Metabolism, in vivo, animals        |
| 03 Complications, Macrovascular             | 12 Genetics                           | 21 Metabolism, in vivo, humans         |
| 04 Complications, Nephropathy               | 13 Health Care Delivery               | 22 Nutrition/Obesity/Exercise          |
| 05 Complications, Neuropathy                | 14 Hormones, Not Insulin              | 23 Pregnancy                           |
| 06 Complications, Ocular                    | 15 Immunology                         | 24 Psychosocial/Behavioral<br>Medicine |
| 07 Diabetes Education                       | 16 Insulin Action                     | 25 Signal Transduction                 |
| 08 Epidemiology                             | 17 Insulin Synthesis/Secretion        | 26 Transplantation                     |
| 09 Foot Care                                | 18 Lipids/Lipoproteins                |  |

**ONLY TYPE ABSTRACT TITLE AND ABSTRACT WITHIN BOX; DO NOT TYPE AUTHOR(S)' NAMES OR LOCATION**

Type only title  
to right of box:

**FOR OFFICE USE ONLY**

Abstract No. \_\_\_\_\_



**FORM B**  
(For review)

**CHECK ONE (See #21):**

- Poster Session Preferred       Oral Session Preferred  
 Poster Session Only       Oral Only  
 No Preference

The author's wishes will be followed if possible.

- I am submitting this abstract after January 6, 1997 as "late-breaking research" (See #33).

**Abstract Category Number:** \_\_\_\_\_  
(Categories listed on pg 4)

**The American Diabetes Association's blinded abstract review process:**

All abstracts submitted to the American Diabetes Association are peer-reviewed through a "blinded" review process. Reviewers are provided copies of the abstract form on this page (Abstract Form B). Please be certain that Abstract Form B does not include the author(s)' names or location(s). Be sure to indicate your presentation preference and the abstract category number on Abstract Form B as you have done on Abstract Form A. Abstract forms which do not comply with these guidelines or instructions on pages 1 and 2 will not be submitted for review. See Abstract Form B sample format below.

**ONLY TYPE ABSTRACT TITLE AND ABSTRACT WITHIN BOX;  
DO NOT TYPE AUTHOR(S)' NAMES OR LOCATION**

Type only title  
to right of box:

Insulin-Mediated Mitogenic Signal Transduction Requires IRS-1.

Abstract data.....

# DUALITY OF INTEREST DISCLOSURE FORM

As a sponsor accredited by the ACCME, the American Diabetes Association must insure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational activities. All presenters participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Significant financial interest or other relationship includes: employment (full or part-time); membership on the board of directors of any fiduciary relationship; membership on a scientific advisory panel, or other standing scientific/medical committee; stock ownership (shares of stock directly owned or controlled, including those owned or controlled by an immediate family member); all consultative or advisory arrangements for which monetary compensation is received; and grants/research support.

The intent of this disclosure is not to prevent a presenter with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the presenter's interests or relationships may influence the presentation with regard to exposition or conclusion. **Each author listed on an abstract must complete and return one of these forms. An author may decline to complete this form, and, in that event, cannot have his/her name on the abstract.**

TITLE OF THE ACTIVITY: 57TH ANNUAL SCIENTIFIC SESSIONS DATE: JUNE 21-24, 1997

ABSTRACT AUTHOR NAME: \_\_\_\_\_

TITLE OF ABSTRACT: \_\_\_\_\_

PLEASE COMPLETE BOTH SECTIONS I AND II:

I. Will your presentation include discussion of any commercial products or services that might be perceived as a duality of interest?

Yes \_\_\_\_\_ No \_\_\_\_\_ (If No, skip to question II)

If YES, do you have a financial interest or other relationship with the manufacturer(s) of any of the products or provider(s) of any of the services you intend to discuss?

Yes \_\_\_\_\_ No \_\_\_\_\_

If YES, please list the manufacturer(s) or provider(s) and describe the nature of the relationship(s): \_\_\_\_\_

\_\_\_\_\_

II. Do you have a relationship(s) with the commercial supporter(s) of this activity?

Yes \_\_\_ No \_\_\_ (Answer "no" unless you have been notified of commercial support for this activity).

If YES, please list the relevant commercial supporter(s) and describe the nature of the relationship(s): \_\_\_\_\_

\_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

**Please photocopy this form and include a completed form for each author with the abstract submission**

ADA will disclose the existence of any significant financial interest or other relationship in the Abstract Book and final program.

**Submission of this form does not: 1) guarantee acceptance of the abstract for presentation (All abstracts are peer-reviewed and not all abstracts are accepted for presentation); or 2) influence the review of the abstracts (Reviewers are not provided copies of the signed *Duality of Interest Disclosure Form*)**

## ABSTRACT PREPARATION CHECKLIST

Two original abstract forms must be submitted as indicated in the Instructions for Preparation of Abstracts (see #3).

Before mailing, please check your abstract submission for the following:

**For both Abstract Form A and Abstract Form B:**

- Is the submission on original abstract forms? (#3)
- Does the heading of the abstract begin to the right of the box located in the left corner of the abstract border, and is the text of the abstract within the border? (#14a, #13)
- Are the first letters of major words in the title capitalized? (#14b)
- Have the instructions for the body of the abstract been followed, including indentation, abbreviation, nonproprietary names, tables, and references? (#15, #16, #17, #18, #19)

- Has the type of presentation preference been indicated? (forms A& B)
- Has the appropriate abstract category number been filled in? (forms A & B)

**For Abstract Form A:**

- Are author(s)' and co-author(s)' names capitalized, and do author(s)' complete first name(s) precede last name(s), in the heading? (#14c)
- Have asterisk(s) been used to designate active member(s) of the Professional Section of the Association in the heading? (#14d)
- Have appropriate numerals to indicate the existence of an author(s)' duality been included in the heading? (#14e)
- Have degrees, academic titles, institutional affiliations, street address, and zip code not been listed in the heading? (#14f, 14g)

- Has the form been signed by an active member of the Professional Section of the Association? (#22)
- Has the corresponding author information been provided, i.e., credentials, institution, and mailing address, as well as an E-mail address (if available) and a fax number? (#24, #28, Form A)
- Has the question regarding the funding of the abstract's research been answered? (#25, Form A)

**For Abstract Form B:**

- Have author(s)' name(s), city(ies) and state(s) been removed from the heading to "blind" the abstract? (#30, Form B)

**For each abstract submission, have the following items been completed and included:**

- Has each author read and signed the *Duality of Interest* form (back of the original Abstract Form B)? (#23)
- Has a self-addressed, stamped postal card been provided if acknowledgement is desired? (#27)
- Has a processing fee of US \$35.00, payable by check to the American Diabetes Association, been enclosed with a payment form, or, has the appropriate credit card information on the payment form been completed and signed by the credit card holder? (#29)
- Have five copies of the front of each form been made and included in the submission packet? (#31)

**"Late-breaking research" abstracts:**

- Have the specific instructions for submission of "late-breaking research" abstracts been followed completely? (#33)



CUT ALONG DOTTED LINE



### PAYMENT FORM

**FOR OFFICE USE ONLY**

Date Rec'd: \_\_\_\_\_  
 Processed By: \_\_\_\_\_  
 No. Submitted: \_\_\_\_\_

**Include this form with your abstract submission.**

Title of Abstract: \_\_\_\_\_

Name of Corresponding Author: \_\_\_\_\_

**Method of Payment**

\_\_\_\_\_ I have enclosed a check in the amount of \$ \_\_\_\_\_ (US\$35 regular or US\$50 "late-breaking" for each abstract -- attach check to this form)

\_\_\_\_\_ I authorize the American Diabetes Association to charge \$ \_\_\_\_\_ (US\$35 regular or US\$50 "late-breaking" for each abstract) to my credit card for my abstract processing fee.



American Express



VISA



Mastercard

Card issued in name of (please print): \_\_\_\_\_

Card Number:                  Exp. Date: \_\_\_\_\_

Signature: \_\_\_\_\_



## FUTURE MEETINGS

### *44th Annual Advanced Postgraduate Course*

January 17 - 19, 1997

New Orleans Hilton Riverside Hotel

New Orleans, Louisiana

### *3rd Annual International Conference and Postgraduate Course*

February 27 - March 2, 1997

Jamaica Grande Resort Hotel

Ocho Rios, Jamaica

Co-sponsored by the University of the West Indies Diabetes Outreach Project  
and the American Diabetes Association

### *4th International Workshop on Gestational Diabetes Mellitus*

March 14 - 16, 1997

Chicago, Illinois

### *57th Annual Meeting and Scientific Sessions*

June 21 - 24, 1997

Boston, Massachusetts

### *58th Annual Meeting and Scientific Sessions*

June 11 - 16, 1998

Chicago, Illinois

For more information and registration forms, contact the  
American Diabetes Association, Meeting Services Department,  
1660 Duke Street, Alexandria, VA 22314-3447 USA;  
phone: (703) 549-1500, ext. 2330; fax: (703) 683-1351;  
E-mail: [meetings@diabetes.org](mailto:meetings@diabetes.org)

*In the real world,*  
your patients need to get a true  
blood glucose value,

*not just a number*

**With an advanced biosensor system, your patients can achieve clinical accuracy in their everyday monitoring.**

The truth is, all blood glucose monitors are accurate under laboratory testing conditions. But in the real world, many factors can alter readings and affect accuracy. Which means your patients may not really be achieving tight blood glucose control. And they may not even know it.

Readings can be affected by everyday things such as dried blood and dirt collecting on the optical window, and bright light overwhelming the photometric system. Humidity or a simple touch can degrade test strip reagents. In addition, an inadequate blood sample can produce a significantly lowered reading. More importantly, test accuracy may be compromised by interactions with drugs, vitamins and other substances present in the body.

But with the advanced biosensor technology of the Precision Q•I•D™ Blood Glucose System, your patients can achieve accurate blood glucose values while testing at home by eliminating common test errors.\* The Precision Q•I•D Monitor requires no cleaning, and its sensors are unaffected by bright light. Each MICROFLO™ test strip reagent pad is protected from degradation caused by humidity\*\* or touching.

It requires only a 5µl blood sample. If needed, a second drop of blood may be added to the test strip to accurately complete a test. In addition, the unique MICROFLO™ test strips make Precision Q•I•D the only system that automatically compensates for the effects of drugs, vitamins and other substances.\*

The Precision Q•I•D Blood Glucose System, with individually foil wrapped test strips, provides true, accurate readings in the real world, not just in the laboratory. And when it comes to your patients and their blood glucose control, that can make all the difference in the world.

For detailed information on advanced biosensor technology, the Precision Q•I•D System, and the importance of real accuracy in the real world contact us at

**1-800-527-3339.**




\* Velazquez F. *Blood Glucose Monitoring: Achieving Accuracy in the Real World*. Boston University Medical Center Hospital, Boston, MA, evaluates common test errors such as dried blood, bright light, humidity and touch, ©1996 Medisense, Inc.

\*\*Foil wrapped test strips

# Accu-Chek® Advantage® System More in a meter. For the most out of life.™


**NEW STRIP—30% LESS BLOOD REQUIRED!**



You can bet they're not thinking about blood glucose testing. You see, with more of the features that people prefer, the Accu-Chek® Advantage® blood glucose monitoring system makes people more comfortable with testing, so they can get the most out of life.

That's what happens when you continually improve on a meter that's already preferred by 3 out of 4\* testers. For example, our latest innovation is a new strip that needs only 9  $\mu$ L—30% less blood.

When you add it all up, the more comfortable your patients are with their meters, the more they'll get out of life—which may be the best feature of all.



\*Of those who expressed a preference in a nationwide trial.  
© 1996 Boehringer Mannheim Corporation. All rights reserved.

**Accu-Chek®**  
BLOOD GLUCOSE MONITORING SYSTEMS  
What it takes to take control™